Hepatoprotective effects of Silybum marianum (silymarin) and Glycyrrhiza glabra (glycyrrhizin) in combination: a possible synergy.
The liver plays a part in many important functions in the body including metabolism, detoxification, and bile secretion. Additionally, it provides protection from exposure to foreign substances by detoxifying and eliminating them. A healthy liver is very important to overall health because it also handles the metabolism and excretion of drugs from the body . Excessive exposure of the liver to environmental toxins, alcohol, drug overdose, and chemotherapeutic agents such as carbon tetrachloride (C[Cl.sub.4]) and thioacetamide can damage the liver and cause alcoholic liver disease, followed by hepatitis and cirrhosis.
For centuries, plants and their extracts have been used in the treatment of various human ailments. The secondary metabolites of some plants have antiviral, immunomodulatory, and anti-inflammatory effects on hepatocytes and have proven to be useful in chronic hepatitis. In the last couple of decades, a strong awareness of the safety, efficacy, and cost effectiveness of drug has been developed among the general public, thus increasing the importance and popularity of herbal medicines deemed to be "natural," as opposed to synthetic drugs .
The traditional herbal treatments for liver diseases have reached new heights with the support of modern evidencebased medicines with promising clinical trial results . Silybum marianum or silymarin (SLN), a plant secondary metabolite, is a complex mixture of four flavonolignan isomers, namely, silybin (60-70%), silychristin (20%), silydianin (10%), and isosilybin (5%) [4, 5]. Although SLN does not have antiviral properties, it has been reported to have antioxidative, anti-inflammatory, immunomodulatory, antilipid, and liver-regenerating properties . The elevated levels of liver enzymes such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) found in liver injuries and chronic diseases are reduced significantly (30-35%) by its use . SLN has been shown to reduce liver fibrosis up to 30-35%, and in few cases it has reversed the liver fibrosis [7, 8].
Glycyrrhizin (GLN), a glycoside of glycyrrhetinic acid and a plant secondary metabolite, is extracted from the roots of Glycyrrhiza glabra, a member of the Leguminosae family. It possesses some nutritive value and medicinal properties [9, 10]. In Japan, GLN is commonly used in the treatment of chronic hepatitis C. GLN significantly reduced plasma ALT and improves liver function in hepatitis C virus infected chronic hepatitis patients . GLN root extract contains saponins, triterpenes, and flavonoids as well as other important constituents, such as phytosterols, choline, and tannins [12-15].
In the laboratory, C[Cl.sub.4] is frequently used to induce liver injuries in animals, mimicking the liver damage caused by various hepatotoxins in humans. C[Cl.sub.4] generates a highly reactive carbon trichloromethyl radical (C[Cl.sub.3]) causing hepatocellular necrosis, which also contributes to oxidative stress and lipid peroxidation . Lipid peroxidation, including chloromethylation and saturation, leads to a functional and structural disruption of the unsaturated fatty acids of the membrane phospholipids . Microarray-based whole transcriptome expression studies of C[Cl.sub.4]-induced rats have found significant changes in the genes involved in stress, DNA damage, cell proliferation, and metabolic enzymes [8, 18, 19]. These profiling studies have established the genetic basis of hepatic toxicity by identifying the molecular responses to acute C[Cl.sub.4] toxicity.
The individual hepatoprotective effects of herbs such as SLN and GLN have been investigatedin hepatotoxic damage. However, there are no studies on the hepatoprotective role of these herbs when administered in combination, which may have a synergistic effect against liver damage, particularly against chronic liver hepatitis. In this study, we investigated the hepatoprotective and antioxidative roles of SLN and GLN on C[Cl.sub.4]-induced liver injury when administered at several different doses, singly or in combination.
2. Materials and Methods
2.1. Laboratory Animals. Adult Wistar male albino rats ranging from 200 to 250 g were obtained from the National Institute of Health, Islamabad, Pakistan. The animals were fed regular diets and were kept at 25[degrees]C with controlled humidity (60%) and lighting (12 h light-dark periods). Water was allowed ad libitum. The study was approved by the Ethics Committee for Scientific Research at the University of Lahore.
2.2. Plant Extracts and Chemicals. The standardized extracts of SLN and GLN were purchased from the Sigma-Aldrich Corporation (St. Louis, MO, USA). Ethanol was used as the solvent for SLN and dimethyl sulfoxide was used for GLN. All other chemical reagents were of analytical grades and were also purchased from Sigma.
2.3. Induction of Hepatic Damage. A modified model of Yadav et al. (2008) was used. Briefly, a dose of 2 mL/kg (50% solution of C[Cl.sub.4] in liquid paraffin) was intraperitoneally administered twice a week to induce hepatic injury in rats .
2.4. Experimental Design. The rats (n = 60) were randomly allocated into six groups. Group A was untreated healthy rats and used as positive control. Groups B, C, D, E, and F received a dose of C[Cl.sub.4] twice a week to induce hepatic injury. Group B was injected with C[Cl.sub.4] alone without SLN or GLN and was used as negative control. The remaining groups (C, D, E, and F) were treated with different concentrations and combinations of the SLN and GLN extracts and were used as test cohorts:
Group A = positive control (healthy untreated rats),
Group B = negative control (C[Cl.sub.4] alone),
Group C = C[Cl.sub.4] + SLN (200 mg/kg),
Group D = C[Cl.sub.4] + GLN (50 mg/kg),
Group E = C[Cl.sub.4] + SLN (100 mg/kg) + GLN (25 mg/kg),
Group F = C[Cl.sub.4] + SLN (200 mg/kg) + GLN (50 mg/kg).
The biochemical assays on the rat's blood and liver tissues were conducted at 2, 4, and 6 weeks to confirm the hepatoprotective effects of SLN and GLN.
2.5. Blood and Serum Separation. Blood (5mL) was withdrawn from the rats' tails and the serum was separated by centrifugation for 10 min at 1500 g. The serum was stored at -60[degrees]C until further biochemical analysis.
2.6. Tissue Homogenate. Liver tissues were homogenized in sodium-phosphate buffer saline (10 mM stock) to yield a 25% homogenate. The homogenate was centrifuged for 15 min at 1500 g and the supernatant was stored at -60[degrees]C until the biochemical analysis was performed.
2.7. Biochemical Assays
2.7.1. Determination of Liver Enzymes and Total Protein. The ALT, AST, and total protein (TP) levels were determined using commercial kits (Biomerieux, USA) based on the established method .
2.7.2. Determination of Alkaline Phosphatase (ALP). ALP was estimated according to the standard method described by Ochoa (1968) using Randox Kits (Randox Laboratories Ltd. Crumlin, UK) .
2.7.3. Estimation of the GSH Content. The content of GSH in the liver was estimated according to the Ellman's method (1959) . Briefly, Ellman's reagent (5,5dithiobisnitrobenzoic acid) reacts with GSH to produce a chromophore (5-thionitrobenzoic acid acid) and oxidized GSH. First, the sum of the reduced and oxidized GSH based on the chemical formula (GSH) t = (GSH) +2 x (GSSG) was used to measure the amount of GSH in the known samples, where (GSH) t = total GSH, (GSH) = reduced GSH, and (GSSG) = glutathione disulfide or oxidized glutathione. Then, a linear equation was generated from several standards of GSH (dynamic range is 0-8 [micro]M GSSG or 0-16 [micro]M GSH) to determine the concentration of an unknown sample . Under the assay conditions, GSSG produced 2 mol equivalents of GSH.
2.7.4. Estimation of the Catalase (CAT) Content. Aebi's method (1984) was utilized for the CAT assay . A neutral phosphate buffer (0.01 M) and hydrogen peroxide ([H.sub.2][O.sub.2]) (2 mM) solution was used to homogenize the liver tissue at <4[degrees]C. This was followed by centrifugation at 2000 g. The enzyme activity was estimated spectrophotometrically by measuring the decrease in absorbance at 230 nm and was expressed as units/g of liver tissue. The absorbance values (OD) of the reaction mixture containing phosphate buffer, [H.sub.2][O.sub.2], and an unknown quantity of the enzyme extract were then compared with a known standard curve of the CAT. Different volumes (10-150 [micro]L) of the catalase formaldehyde standard (4.25 mM stock solution) were diluted in the buffer to a final volume of 1000 [micro]L to yield a final standard concentration ranging from 5 to 75 [micro]M.
2.7.5. Estimation of the Thiobarbituric Acid Reactive Substances (TBARS) Content. Estimation of lipid peroxidation in liver tissues was colorimetrically determined by measuring the TBARS  based on the method established by Ohkawa et al. (1979). Briefly, 0.2 mL of 8.1% sodium dodecyl sulphate, 1.5 mL of 20% acetic acid, and 1.5 mL of 0.8% thiobarbituric acid were added to 0.2 mL of the homogenized sample. It was vortexed for 2 min and then centrifuged at 1500 g for 10 min. The OD of the upper organic layer was then measured at 532 nm. The level of lipid peroxides was expressed as mM of TBARS/100 g of liver tissue.
2.7.6. Estimation of the Super Oxide Dismutase (SOD) Content. The method of Nishikimi et al. (1972), which was later modified and improved by Kakkar et al. (1984), was adopted to measure the SOD activity [27,28]. Briefly, 1.2 mL of sodium pyrophosphate buffer (pH 8.3, 0.052 M), 0.1 mL of phenazine methosulphate (186 [micro]M), 0.3 mL of nitro blue tetrazolium (300 [micro]M), and 0.2 mL of dihydronicotinamide adenine dinucleotide (NADH) (750 [micro]m) were added to 0.1 mL of the sample. The reaction was initiated by adding NADH followed by incubation at 30[degrees]C for 90 sec. The reaction was later terminated by the addition of 0.1 mL glacial acetic acid. Then, 4.0 mL n-butanol was added to the reaction mixture followed by a thorough mixing. The reaction mixture was allowed to stand for 10 min, followed by centrifugation at 1500 g to separate the upper butanol layer from the sample reaction mixture. The presence of chromogen was measured at 560 nm against n-butanol as the control. A standard curve of known SOD concentrations was then used to estimate the unknown SOD concentrations. The standard stock of SOD ranging from 10 to 200 [micro]L was diluted in the buffer to a final volume of 1000 [micro]L to produce a standard with SOD activity ranging from 0.025 to 0.250 U/mL.
2.8. Histopathological Examinations. The rats' livers were fixed in 10% formalin for 24 h. This was followed by tap water washing before dehydration using absolute ethyl alcohol. Xylene was used to clean the specimens, which were later embedded in paraffin in a hot air oven at 50[degrees]C for 24 h. The processed specimens were fixed in paraffin tissues blocks. A sledge microtome was used to produce tissue sections of 4 [micro]m thickness on glass slides. For histopathological examinations, the slides were deparaffinized and stained with hematoxylin and eosin  and examined at various time intervals (2, 4, and 6 weeks).
2.9. Statistical Analysis. A CoStat computer package (version 6.4) (CoHort software, Monterey, CA) was used for statistical analysis. The mean [+ or -] SEM was used to express the results. A P value of <0.05 was considered to be significant.
3.1. The Effects of SLN and GLN on C[Cl.sub.4]-Induced Changes in Serum ALT, AST, ALP, and TP Levels. A significant increase in the serum levels of the liver enzymes (ALT, AST, and ALP) and a significant decrease in TP levels were observed in all of the animals receiving C[Cl.sub.4] alone (Group B) confirming that the dose is adequate and suitable for the induction of hepatic injury (Table 1). Both SLN and GLN, when administered singly (Groups C and D), ameliorated the ALT, AST, ALP, and TP levels indicating that the herbs have hepatoprotective activity even when used alone. When the herbs were used in combination (Group E), the levels were markedly ameliorated indicating that the herbs may have synergistic effects. The highest liver protective effect was observed in Group F, where the animals received the highest dose of the herbs given in combination.
3.2. The Effects of SLN and GLN on C[Cl.sub.4]-Induced Changes in Antioxidant Enzymes (SOD and CAT) Activities in the Liver. CCl4 significantly reduced the activity of SOD (from 76.75 to 54.59 [micro]g/mg) and CAT (from 33.16 to 20.25 g/mg) in the rats' livers. Both SLN and GLN increased the activities of SOD and CAT in all treated groups (C, D, E, and F). Again, the SLN and GLN combination at the higher dose (Group F) yielded the best hepatoprotective effect with an almost 100% recovery (Table 2).
3.3. The Effects of SLN and GLN on C[Cl.sub.4]-Induced Changes in Nonenzymatic Antioxidant (GSH) Activity in the Liver. The activity of GSH significantly decreased (from 7.84 to 2.99 [micro]g/mg or by 61.86%) in the rats' livers following hepatic injury due to C[Cl.sub.4] exposure. The highest recovery of GSH (at 7.90 [micro]g/mg protein) was again observed in animals receiving SLN and GLN in combination and the group of animals that received the highest dose (Group F) had the best hepatoprotective effects (Table 2).
3.4. The Effects of SLN and GLN on C[Cl.sub.4]-Induced Changes in the Lipid Peroxidation (TBARS) of the Rats' Liver. An increase of 82.81% in the levels of TBARS (80.51 nmol/g tissue) was recorded in the liver of rats treated with C[Cl.sub.4] when compared to that of the normal control animals (44.04 nmol/g tissue) (Table 2). Again, the animals receiving SLN and GLN in combination showed significant recovery of the TBARS levels almost to normal indicating that the herbs may have synergistic effects for liver protection.
3.5. Time-Dependent Effects of SLN and GLN. Overall, SLN and GLN ameliorated the serum levels of the liver enzymes (ALT, AST, and ALP) and TP levels the most when administered for 6 weeks when compared to 4 or 2 weeks (Figure 1). The recovery of ALT (39%, 46%, and 91%), AST (49%, 75%, and 100%), and ALP (27%, 30%, and 65%) continually increased towards normalcy over the time course of the experiment (2nd, 4th, and 6th week). As expected, the highest recovery for the SOD and CAT enzymes (24.16% and 42.12%) was observed in group F at the 6th week following the administration of the herbs. The activity of GSH significantly increased during the 2nd (5.52 [micro]g/mg), 4th (9.15 [micro]g/mg), and 6th (9.05 [micro]g/mg) weeks indicating that SLN and GLN had time-dependent effects in reducing liver damage. Similarly, the TBARS levels were also significantly higher and were almost back to normal by the 6th week of the experiment indicating that by six weeks the maximum hepatoprotective effects were reached by SLN and GLN, especially when administered in combination.
3.6. Histopathological Findings. The histopathological observations (Figure 2) following two weeks of C[Cl.sub.4] exposure indicate the presence of liver injury as evidenced by hepatocyte proliferation, necrosis, diffused Kupffer cells, binucleated cells, few mitotic configurations, congestion of central and portal veins ballooning degeneration, and sinusoidal dilation when compared to the animals in the normal control group. These alterations were significantly ameliorated by the combination of SLN and GLN treatments, where only minor hepatocellular necrosis, inflammatory cell infiltration, and mild portal inflammation were observed.
C[Cl.sub.4] is widely used to induce liver injury in laboratory rodents [16, 30-32]. Increased levels of serum transaminases reflect hepatic injury as the enzymes are released into circulation following the exposure . C[Cl.sub.4] initially causes necrosis and steatosis and may lead to fibrosis, cirrhosis, and hepatocellular carcinoma when administered at higher dosages [34,35]. Because the changes related to C[Cl.sub.4]-induced liver injury are in close propinquity to those of viral hepatitis , C[Cl.sub.4]-induced hepatic insult was selected in the current study as the experimental model to investigate the effects of SLN and GLN standardized extracts used singly and in combination at different dosages and over a time course of therapy.
It is widely accepted that, in hepatic parenchyma cells, cytochrome P450-dependant monooxygenases convert the accumulated C[Cl.sub.4] into C[Cl.sub.3] radicals. In addition to the alkylation of cellular proteins, C[Cl.sub.3] attacks the polyunsaturated fatty acids to produce lipid peroxides that are responsible for the hepatotoxicity and alteration of hepatic enzyme levels . The disturbance of hepatocytic transport function during hepatic injury causes an altered permeability of the membrane leading to the leakage of enzymes from the cells , thus resulting in the reduction of the ALT, AST, and ALP levels in the hepatic cells and elevation of their levels in the serum . Rajesh and Latha have also shown that cellular leakage and liver cell membrane integrity are linked to increased levels of liver enzymes . ALT and AST are enzymes present in hepatocytes and liver parenchymal cells, respectively. Increased levels of these transaminases are indicators of liver cellular integrity. Large bile duct obstruction and infiltrative diseases of the liver lead to increased ALP levels in plasma because ALP is present in the cells lining the biliary ducts of the liver.
In the present study, C[Cl.sub.4] was administered to inflict liver injury and standardized extracts of SLN and GLN were administered to investigate their hepatoprotective effects. C[Cl.sub.4] was found to increase the levels of ALT, AST, and ALP while decreasing the TP levels, thus confirming the presence of liver injury, as also reported by Yadav et al. . Interestingly, the animals that received the SLN and/or GLN therapy showed liver recovery that approached normalcy with increasing time courses of administration regardless of whether they were administered singly or in combination.
At the lowest levels of ALT, AST, and ALP for the animals in groups E and F, the combined therapy of SLN and GLN was more effective than when they were used individually and the extract with the higher dose combination was the most effective. The extracts seem to act synergistically to ameliorate the hepatic injuries. In another study, Yadav et al. have also shown that the combination therapy of SLN and Phyllanthus amarus extracts has marked hepatoprotective effects as indicated by significant changes in liver enzymes . The drugs in combination produced higher liver protection than when used alone; thus combination therapy can lead to synergistic activity [20, 40]. Our study is the first to show that SLN and GLN have marked hepatoprotective effects when used in combination at 200 mg/kg and 50 mg/kg, respectively.
The overproduction of reactive oxygen species (ROS) in hepatocytes may cause cell death by damaging DNA, proteins, lipids, and carbohydrates [41, 42]. The imbalance between the production of ROS and antioxidant defense causes oxidative stress, leading to significant physiological challenges. The increased levels of TBARS (80.50 nmol/g versus 44.23 nmol/g) and decreased levels of SOD (54.59 [micro]g/mg versus 76.75 [micro]g/mg) and CAT (20.25 [micro]g/mg versus 33.17 [micro]g/mg) in our study suggest that excessive lipid peroxidation results in tissue damage and the failure of antioxidative defenses to mop up the excess production of ROS . The administration of SLN and GLN helped to ameliorate all these cellular changes by increasing the enzymatic antioxidants (SOD, CAT) as well as nonenzymatic antioxidant (GSH) and reducing the TBARS level in the serum. Our findings indicate that SLN and GLN have the ability to scavenge the ROS to overcome the oxidative damage caused by C[Cl.sub.4] in artificially induced hepatic injury and that this recovery occurs after six weeks of treatment.
The effects of SLN and GLN were investigated in time-dependent studies at 2, 4, and 6 weeks of treatment to determine when the hepatoprotective effect started to show fully. A continuously decreasing trend in the ALT, AST, and ALP values was recorded after 2nd, 4th, and 6th week in group F rats, which had received a combination of SLN and GLN at the highest dosages. The time-dependent studies revealed that the healing process for serum enzymes induced by SLN and GLN is directly proportional to the time period of treatment. The time-dependent recovery of serum enzymes, SOD, CAT, GSH, and TBARS shows a similar behavior; their maximum recovery was observed after the 6th week of the experiment.
A number of histopathological abnormalities such as cellular necrosis, dilated hepatic sinusoids, degenerated hepatocytes, apoptotic bodies, binucleated cells, focal necrosis, diffuse Kupffer cells, and steatosis are evident in rats receiving C[Cl.sub.4] as a hepatotoxin. Portal areas infiltrated by mononuclear inflammatory cellular exudates mainly contain lymphocytes. The results of the current study demonstrate that the combined therapy of SLN and GLN may help in the healing of the necroinflammatory lesions induced by C[Cl.sub.4]. Previous work by Shalan et al. (2005) and Shaker et al. (2010) clearly demonstrated that SLN has anti-inflammatory potential and can alter histopathological changes induced by C[Cl.sub.4], such as ballooning, necrosis, and inflammatory infiltration of lymphocytes [44,45]; our results confirm these findings.
By definition, synergistic effects can also lead to the enhancement of the bioavailability of one of the extracts if the constituents of one extract affect the others or interact with one another; this can also improve their solubilities . Although it has been hypothesized that the combination therapy of SLN and GLN exhibits synergistic activity and confers higher liver protection, the synergistic effects need to be further confirmed using the Berenbaum method . In follow-up studies, the synergistic effects of SLN and GLN will be further investigated using detailed pharmacological, toxicological, and clinical studies.
In conclusion, SLN and GLN have hepatoprotective effects against C[Cl.sub.4]-induced liver injury and are more effective in combination than when used individually. Our findings strongly suggest that the combination of drugs at higher doses, that is, SLN (200mg/kg) and GLN (50mg/kg), may have synergistic activity and confer the best hepatoprotective effects. The time-dependent studies revealed that the healing process for serum enzymes induced by SLN and GLN is directly proportional to the time course of treatment and that the herbs achieve an almost complete healing after six weeks of continuous administration.
Conflict of Interests
The authors declare that there is no conflict of interests.
Arif Malik and Mahmood Rasool designed the study and drafted the paper. Javed Iqbal, Hafiza Sobia Ramzan, and Muhammad Saeed Qureshi performed the experiments. Mahmood Husain Qazi and Muhammad Asif helped to collect the data. Javed Iqbal, Mohammed Hussain Al-Qahtani Mohammad Amjad Kamal, Siew Hua Gan, and Adeel Gulzar Ahmed Chaudhary helped to write the paper. Sajjad Karim and Siew Hua Gan analyzed the data and critically reviewed the paper. Mahmood Rasool, Javed Iqbal, and Arif Malik contributed equally, thus sharing first authorship.
This research was funded and supported by the Institute of Molecular Biology and Biotechnology, University of Lahore, Pakistan. The authors are also thankful to King Abdullah City for Science and Technology, Riyadh, Saudi Arabia (KACST Strategic Project ID 10-BIO1073-03 and 10-BIO1258-03), and Deanship of Scientific Research and Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia, for research funding and support.
 S. C. Pradhan and C. Girish, "Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine," Indian Journal of Medical Research, vol. 124, pp. 491-504, 2006.
 Z. Asghar and Z. Masood, "Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radicals in vitro," Pakistan Journal of Pharmaceutical Sciences, vol. 21, no. 3, pp. 249-254, 2008.
 S. P. Thyagarajan, S. Subramanian, T. Thirunalasundari, P. S. Venkateswaran, and B. S. Blumberg, "Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus," The Lancet, vol. 2, no. 8614, pp. 764-766,1988.
 S. M. Shaarawy, A. A. Tohamy, S. M. Elgendy et al., "Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity," International Journal of Biological Sciences, vol. 5, no. 6, pp. 549-557, 2009.
 R. Saller, R. Meier, and R. Brignoli, "The use of silymarin in the treatment of liver diseases," Drugs, vol. 61, no. 14, pp. 2035-2063, 2001.
 H. A. Salmi and S. Sarna, "Effect of silymarin on chemical, functional, and morphological alterations of the liver: a doubleblind controlled study," Scandinavian Journal of Gastroenterology, vol. 17, no. 4, pp. 517-521,1982.
 G. Boigk, L. Stroedter, H. Herbst, J. Waldschmidt, E. O. Riecken, and D. Schuppan, "Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats," Hepatology, vol. 26, no. 3, pp. 643-649, 1997.
 P. S. Haddad, Y. Haddad, D. Vallerand, and A. Brault, "Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis," Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 647903, 2011.
 G. R. Fenwick, J. Lutomski, and C. Nieman, "Liquorice, Glycyrrhiza glabra L.: composition, uses and analysis," Food Chemistry, vol. 38, no. 2, pp. 119-143,1990.
 R. Wang, J. Kong, D. Wang, L. L.-M. Lien, and E. J.-C. Lien, "A survey of Chinese herbal ingredients with liver protection activities," Chinese Medicine, vol. 2, article 5, 8 pages, 2007
 M. Okuno, S. Kojima, and H. Moriwaki, "Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives," Journal of Gastroenterology and Hepatology, vol. 16, no. 12, pp. 1329-1335, 2001.
 J. Snow, "Glycyrrhiza glabra monograph," The Protocol Journal of Botanical Medicine, vol. 1, no. 3, pp. 9-14,1996.
 T. Fukai, A. Marumo, K. Kaitou, T. Kanda, S. Terada, and T. Nomura, "Anti-Helicobacter pylori flavonoids from licorice extract," Life Sciences, vol. 71, no. 12, pp. 1449-1463, 2002.
 I. A. Rossi, Medicinal Plants of the World. Vol 2: Chemical Constituents, Traditional and Modern Uses, Human Press, otowa, NJ, USA, 1999.
 T. P. Arystanova, M. P. Irismetov, and A. O. Sopbekova, "Chromatographic determination of glycyrrhizinic acid in Glycyrrhiza glabra preparation," Chemistry of Natural Compounds, vol. 37, no. 1, pp. 89-90, 2001.
 D. Taieb, C. Malicet, S. Garcia et al., "Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity," Hepatology, vol. 42, no. 1, pp. 176-182, 2005.
 R. O. Recknagel, "A new direction in the study of carbon tetrachloride hepatotoxicity," Life Sciences, vol. 33, no. 5, pp. 401-408, 1983.
 B. Jiang and C. H. Yin, "Study on the bioavaibility of silymarin-phospholipid complex in rabbit," Chinese Pharmaceutical Journal, vol. 33, pp. 589-600, 2002.
 S.-H. Kim, H. J. Cheon, N. Yun et al., "Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fibrosis," Journal of Pharmacological Sciences, vol. 109, no. 1, pp. 119-127, 2009.
 N. P. Yadav, A. Pal, K. Shanker et al., "Synergistic effect of silymarin and standardized extract of Phyllanthus amarus against C[Cl.sub.4]-induced hepatotoxicity in Rattus norvegicus," Phytomedicine, vol. 15, no. 12, pp. 1053-1061, 2008.
 S. Reitman and A. S. Frankel, "A colourimetric method for the determination of serum glutamyl oxaloacetatic and glutamyl pyruvate transaminase," The American Journal of Clinical Pathology, vol. 28, pp. 56-58,1957.
 E. A. Ochoa, "Serum alkaline phosphatase using phenolphthalein monophosphate in a 12-channel automated system," Clinical Biochemistry, vol. 2, no. C, pp. 71-80,1968.
 G. L. Ellman, "Tissue sulfhydryl groups," Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70-77,1959.
 F. Tietze, "Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues," Analytical Biochemistry, vol. 27, no. 3, pp. 502-522,1969.
 H. Aebi, "Catalase in vitro," Methods in Enzymology, vol. 105, pp. 121-126, 1984.
 H. Ohkawa, N. Ohishi, and K. Yagi, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction," Analytical Biochemistry, vol. 95, no. 2, pp. 351-358,1979.
 M. Nishikimi, N. Appaji Rao, and K. Yagi, "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen," Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 849-854, 1972.
 P. Kakkar, B. Das, and P. N. Viswanathan, "A modified spectrophotometric assay of superoxide dismutase," Indian Journal of Biochemistry and Biophysics, vol. 21, no. 2, pp. 130-132,1984.
 A. Smith and J. A. Bruton, Colour Atlas of Histological Staining Techniques, Wolfe Medical Publications, London, UK, 1978.
 R. Sallie, J. M. Tredger, and R. Williams, "Drugs and the liver. Part 1: testing liver function," Biopharmaceutics and Drug Disposition, vol. 12, no. 4, pp. 251-259,1991.
 V. Ferencz, C. Horvath, B. Kari et al., "Bone disorders in experimentally induced liver disease in growing rats," World Journal of Gastroenterology, vol. 11, no. 45, pp. 7169-7173, 2005.
 W. F. Seifert, A. Bosma, A. Brouwer et al., "Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats," Hepatology, vol. 19, no. 1, pp. 193-201,1994.
 T. Fu ji, B. C. Fuchs, S. Yamada et al., "Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor," BMC Gastroenterology, vol. 10, article 79, 2010.
 R. A. Pierce, M. R. Glaug, R. S. Greco, J. W. Mackenzie, C. D. Boyd, and S. B. Deak, "Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats," Journal of Biological Chemistry, vol. 262, no. 4, pp. 1652-1658,1987
 R. Perez Tamayo, "Is cirrhosis of the liver experimentally produced by C[Cl.sub.4] an adequate model of human cirrhosis?" Hepatology, vol. 3, no. 1, pp. 112-120,1983.
 D. RUBINSTEIN, "Epinephrine release and liver glycogen levels after carbon tetrachloride administration," The American journal of physiology, vol. 203, pp. 1033-1037,1962.
 A. Bishayee, A. Sarkar, and M. Chatterjee, "Hepatoprotective activity of carrot (Daucus carota L.) against carbon tetrachloride intoxication in mouse liver," Journal of Ethnopharmacology, vol. 47, no. 2, pp. 69-74,1995.
 H. J. Zimmerman and L. B. Seeff, "Enzymes in hepatic disease," in Diagnostic Enzymology, E. L. Googly, Ed., Lea and Febiger, Philadelphia, Pa, USA, 1970.
 M. G. Rajesh and M. S. Latha, "Preliminary evaluation of the antihepatotoxic activity of Kamilari, apolyherbal formulation," Journal of Ethnopharmacology, vol. 91, no. 1, pp. 99-104, 2004.
 H. F. Chambers, "Antimicrobial agents: general considerations," in Goodman and Gillmans-the Pharmacological Basis of Therapeutics, J. G. Hardman and L. E. Limbird, Eds., pp. 1162-1163, McGraw-Hill, New York, NY, USA, 2001.
 P. Ahmad, C. A. Jaleel, M. M. Azooz, and G. Nabi, "Generation of ROS and non-enzymatic antioxidants during abiotic stress in plants," Botany Research International, vol. 2, no. 1, pp. 11-20, 2009.
 N. Tuteja, M. B. Singh, M. K. Misra, P. L. Bhalla, and R. Tuteja, "Molecular mechanisms of DNA damage and repair: progress in plants," Critical Reviews in Biochemistry and Molecular Biology, vol. 36, no. 4, pp. 337-397, 2001.
 L. Ranawat, J. Bhatt, and J. Patel, "Hepatoprotective activity of ethanolic extracts of bark of Zanthoxylum armatum DC in C[Cl.sub.4] induced hepatic damage in rats," Journal of Ethnopharmacology, vol. 127, no. 3, pp. 777-780, 2010.
 M. G. Shalan, M. S. Mostafa, M. M. Hassouna, S. E. H. El-Nabi, and A. El-Refaie, "Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements," Toxicology, vol. 206, no. 1, pp. 1-15, 2005.
 E. Shaker, H. Mahmoud, and S. Mnaa, "Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage," Food and Chemical Toxicology, vol. 48, no. 3, pp. 803-806, 2010.
 H. Wagner and G. Ulrich-Merzenich, "Synergy research: approaching a new generation of phytopharmaceuticals," Phytomedicine, vol. 16, no. 2-3, pp. 97-110, 2009.
 M. C. Berenbaum, "What is synergy?" Pharmacological Reviews, vol. 41, no. 2, pp. 93-141, 1989.
Mahmood Rasool, (1) Javed Iqbal, (2) Arif Malik, (3) Hafiza Sobia Ramzan, (3) Muhammad Saeed Qureshi, (3) Muhammad Asif, (4) Mahmood Husain Qazi, (5) Mohammad Amjad Kama (l,6) Adeel Gulzar Ahmed Chaudhary, (1) Mohammed Hussain Al-Qahtani, (1) Siew Hua Gan, (7) and Sajjad Karim (1)
(1) Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Post Box No. 80216, Jeddah 21589, Saudi Arabia
(2) Department of Pharmacy, University of Lahore, Pakistan
(3) The Institute of Molecular Biology and Biotechnology, University of Lahore, Pakistan
(4) Department of Biotechnology and Informatics, BUITEMS, Quetta, Pakistan
(5) Center for Research in Molecular Medicine, University of Lahore, Pakistan
(6) King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
(7) Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Correspondence should be addressed to Siew Hua Gan; firstname.lastname@example.org and Sajjad Karim; email@example.com
Received 1 December 2013; Accepted 12 February 2014; Published 25 March 2014
Academic Editor: Marcella Reale
TABLE 1: The effects of SLN and GLN on liver function. Group ALT (IU/L) AST (IU/L) A 29.37 [+ or -] 0.77 31.29 [+ or -] 0.54 B 94.83 [+ or -] 2.61 73.21 [+ or -] 4.44 C 63.68 [+ or -] 11.52 51.49 [+ or -] 5.12 D 59.40 [+ or -] 7.72 51.93 [+ or -] 6.17 E 50.42 [+ or -] 6.85 41.63 [+ or -] 5.73 F 41.32 [+ or -] 2.88 37.19 [+ or -] 5.93 Group ALP (IU/L) TP (IU/L) A 81.54 [+ or -] 1.34 6.22 [+ or -] 0.03 B 157.96 [+ or -] 4.66 4.12 [+ or -] 0.20 C 139.95 [+ or -] 14.11 5.54 [+ or -] 0.63 D 141.41 [+ or -] 16.45 5.60 [+ or -] 0.66 E 141.65 [+ or -] 6.29 3.98 [+ or -] 0.16 F 129.86 [+ or -] 8.76 3.87 [+ or -] 0.18 Values are expressed as the means [+ or -] SEM; n = 10 for each treatment group. TABLE 2: The effects of SLN and GLN on SOD, CAT, GSH, and TBARS levels. Group SOD ([micro]g/mg tissue) CAT ([micro]g/mg protein) A 76.75 [+ or -] 0.06 33.17 [+ or -] 0.17 B 54.59 [+ or -] 1.71 20.26 [+ or -] 1.45 C 66.24 [+ or -] 3.73 35.74 [+ or -] 4.37 D 66.67 [+ or -] 4.25 40.41 [+ or -] 1.85 E 64.66 [+ or -] 4.80 45.50 [+ or -] 2.80 F 67.68 [+ or -] 6.36 45.65 [+ or -] 4.39 Group GSH ([micro]g/mg protein) TBARS (nmol/g tissue) A 7.84 [+ or -] 0.06 44.04 [+ or -] 0.12 B 2.99 [+ or -] 0.75 80.51 [+ or -] 4.35 C 4.99 [+ or -] 0.77 61.83 [+ or -] 3.18 D 7.29 [+ or -] 1.09 55.20 [+ or -] 3.19 E 7.60 [+ or -] 1.06 51.40 [+ or -] 1.78 F 7.91 [+ or -] 0.97 46.56 [+ or -] 2.35 Values are expressed as the means [+ or -] SEM; n = 10 for each treatment group.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Research Article|
|Author:||Rasool, Mahmood; Iqbal, Javed; Malik, Arif; Ramzan, Hafiza Sobia; Qureshi, Muhammad Saeed; Asif, Muh|
|Publication:||Evidence - Based Complementary and Alternative Medicine|
|Article Type:||Clinical report|
|Date:||Jan 1, 2014|
|Previous Article:||The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.|
|Next Article:||External application of traditional Chinese medicine for venous ulcers: a systematic review and meta-analysis.|